Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The NIH Blueprint for Neuroscience Research is preparing to continue the Blueprint Neurotherapeutics Network for Small Molecules (BPN-SM), a program designed to accelerate the translation of investigator-initiated small-molecule therapeutics toward clinical testing. This initiative provides researchers with access to NIH-supported experts and contract research organizations specializing in medicinal chemistry, pharmacokinetics, toxicology, formulation, GMP synthesis, and Phase I clinical trials, enabling them to advance promising compounds while retaining intellectual property and gaining practical experience in translational drug development. The program operates under a phased cooperative agreement model, where ongoing support is contingent upon meeting annual feasibility milestones, allowing for high-risk, high-reward projects to progress under close scientific collaboration between principal investigators and NIH staff, who play an active role in project management alongside external specialists. The program specifically focuses on small molecules due to distinct developmental, regulatory, and manufacturing pathways that differentiate them from biologics. Applications are not currently being accepted, but this notice serves to inform potential applicants of the upcoming opportunity, giving them ample time to build the necessary cross-disciplinary teams and refine their project proposals to meet the program’s rigorous standards. The initiative is managed by the National Institutes of Health under the Department of Health and Human Services, with inquiries directed to the Blueprint Neurotherapeutics Team. The goal is to de-risk candidate therapeutics to the point where industry partners can assume late-stage development, ultimately facilitating the delivery of new treatments to patients. The program does not solicit applications at present but encourages early preparation through collaboration and strategic planning.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.
The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency